ASCO 2018 | KEYNOTE-040: groundbreaking results for pembrolizumab in head and neck cancer

Ezra Cohen

Metastatic head and neck cancer that has progressed following platinum therapy generally has a very poor prognosis. In this video, Ezra Cohen, MD, FRCPC, FASCO, of the University of California, San Diego, CA, discusses the KEYNOTE-040 trial (NCT02252042) at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. This study delivered groundbreaking results for treating this group of head and neck cancers with pembrolizumab over three different standard of care chemotherapies. Response rate, survival and quality of life were all improved with pembrolizumab, and Dr Cohen discusses the implications of these data.

Share this video